Keyphrases
Drug Metabolism
100%
Humanized
61%
Cytochrome P450 1A1 (CYP1A1)
38%
Cytochrome P450 1A2 (CYP1A2)
38%
Tumor Research
30%
Induction Studies
30%
HepaRG
30%
HepaRG Cells
30%
Predictive Power
30%
ERK Activity
30%
Syngeneic
30%
BRAF V600E
30%
Mathematical Modeling
30%
Humanized Mouse Model
30%
Drug Disposition
30%
ERK Cascade
30%
Knock-in Mouse Model
30%
Differentiation Protocol
30%
HepG2 Cells
30%
Hepatocytes
30%
Drug Interactions
30%
Xenograft
30%
Dabrafenib
30%
MEK-ERK
30%
P450s
30%
Clinical Trial Design
30%
Antitumor
30%
Cytochrome P450 (CYP450)
28%
Trametinib
24%
P450
23%
Drug Candidates
23%
Vertical Inhibition
18%
Hepatic Metabolism
18%
Human-relevant
15%
Drug Metabolizing Capacity
15%
Induction Protocol
15%
Regulatory Guidelines
15%
Business Secrets
15%
Pharmacologically Active
15%
Proteomic Study
15%
P450 Induction
15%
HepG2 Cell Line
15%
Pharmacokinetic Evaluation
15%
Human Hepatocytes
15%
Metabolism Study
15%
In Vitro Model
15%
Hepatocyte-like Cells
15%
Anticancer Drugs
15%
Gene Family
15%
Drug Efficacy
15%
Popular
15%
Protein Expression
15%
Hepatic Toxicity
15%
Species Differences
15%
Safety Assessment
15%
Melanoma Cells
13%
Chemical Reaction
12%
Drug Resistance
12%
Molecular Mechanism
12%
Metabolism
8%
Drug Efficacy Evaluation
7%
Murine Melanoma Cells
7%
Personalized Treatment
7%
Mouse Genome
7%
Patient-derived Xenograft
7%
Regulatory Approval
7%
Drug Development
7%
Toxicological Properties
7%
Major Gene
7%
Immunodeficient
7%
Clinical Setting
7%
Patient Response
7%
Xenograft Studies
7%
Clinical Trials
7%
Attrition
7%
Confounding Factors
7%
Pharmacokinetics-pharmacodynamics (PK-PD)
7%
Specific Types
7%
Pharma
7%
Tumor
7%
Wasted Time
7%
Transgenic Mouse Model
7%
Target Validation
7%
Cytochrome P450 3A4 (CYP3A4)
7%
Preclinical Research
7%
Small Fraction
7%
Transcription Factor
7%
Drug Type
7%
Mouse Model
7%
Genetically Engineered Mouse Models
7%
Metabolism Rate
7%
Preclinical Application
7%
Pharmacokinetics
7%
Toxicology
7%
RAG2
7%
Development Work
7%
Significant Benefit
7%
Rodent Species
7%
Efficacy Study
7%
Informed Design
7%
Differential Activation
7%
Oncology Setting
7%
Preclinical Development
7%
Cytochrome P450 2D6 (CYP2D6)
7%
In Vivo Pharmacokinetics
7%
Drug Transporters
7%
CYP2C9
7%
Pharmacodynamic Properties
7%
Drug Discovery
7%
Animal Data
7%
CYP3A7
7%
Monkey
7%
Pharmacokinetic Data
7%
Pharmacology
7%
Cancer Treatment
7%
Redundancy
7%
Pharmacokinetic Properties
7%
Mass-action Kinetics
6%
ERK Pathway
6%
Melanoma
6%
Component Concentration
6%
Mutant BRAF
6%
Dose Combination
6%
ATP Level
6%
In Vitro Data
6%
BRAF Inhibitor (BRAFi)
6%
Dual Inhibition
6%
Cell Proliferation
6%
Computational Simulation
6%
BRAF V600E mutant
6%
Multiple Components
6%
Signaling Dynamics
6%
Standard of Care
6%
Temporal Evolution
6%
BRAF-mutant Melanoma
6%
Ordinary Differential Equations
6%
Mechanistic Mathematical Models
6%
MEK Inhibitor (MEKi)
6%
Quantitative Methods
6%
Gene Locus
5%
Enzyme Kinetics
5%
Relative Contribution
5%
Liver
5%
Tetrachlorodibenzodioxin
5%
Substrate Specificity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Metabolism
100%
Mouse
80%
Cytochrome P450
42%
Mouse Model
38%
CYP1A2
38%
Cytochrome P450 1A1
38%
Clinical Trial
38%
Pharmacokinetics
37%
Neoplasm
30%
Knockout Mouse
30%
Dabrafenib
30%
Drug-Drug Interaction
30%
Melanoma
26%
Trametinib
24%
Drug Development
15%
Anticarcinogen
15%
Drug Resistance
12%
Cytochrome
12%
Safety Assessment
10%
Dimethyl Sulfoxide
10%
Substrate Specificity
8%
Enzyme Kinetics
8%
2,3,7,8-Tetrachlorodibenzodioxin
8%
Pharmacodynamics
7%
Efficacy Study
7%
Genetically Engineered Mouse Strain
7%
Clinical Research
7%
Preclinical Study
7%
Transgenic Mouse
7%
Lead Compound
7%
CYP2C9
7%
Malignant Neoplasm
7%
Haplorhini
7%
Transcription Factors
7%
CYP2D6
7%
CYP3A4
7%
CYP3A7
7%
Drug Discovery
7%
Adenosine Triphosphate
6%
Mitogen Activated Protein Kinase Kinase Inhibitor
6%